Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 14:3:1007593.
doi: 10.3389/falgy.2022.1007593. eCollection 2022.

Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

Antolín López-Viña  1 , Rocío M Díaz Campos  2 , Andrea Trisan Alonso  1 , Carlos Melero Moreno  3
Affiliations

Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

Antolín López-Viña et al. Front Allergy. .

Erratum in

Abstract

In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with asthma indication are omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. Tezepelumab is approved by the Food and Drug Administration (FDA) in the United States and, recently, by the European Medicines Agency (EMA). All these biological drugs have shown their efficacy in clinical trials, especially in reducing exacerbations, improving asthma control, quality of life, pulmonary function, and withdrawing systemic corticosteroids or at least reducing their daily dose, with some differences between them. Except for mepolizumab and reslizumab, biological drugs have different targets and thus different therapeutic indications should be expected; however, in some patients, more than one drug could be indicated, making the election more difficult. Because there are no direct comparisons between biological drugs, some biomarkers are used to choose between them, but they are not unbeatable. In this article, an algorithm to choose the first biological drug in a specific patient is proposed based on different study results and patient' characteristics.

Keywords: T2 severe asthma; biomarkers; exacerbations; monoclonal antibodies; systemic corticosteroid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Algorithm to choose a monoclonal antibody.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Utility of the Basophil Reactivity Test in the Clinical Management of People with Severe Uncontrolled Asthma.
    García Ródenas MDM, Hernández Blasco LM, Fernández Sánchez FJ, Marco de la Calle FM, Pascual-Lledó JF, Sánchez Barbie Á, Fernández Aracil C. García Ródenas MDM, et al. J Asthma Allergy. 2025 Apr 7;18:519-528. doi: 10.2147/JAA.S505951. eCollection 2025. J Asthma Allergy. 2025. PMID: 40224171 Free PMC article.
  • Monoclonal antibodies in severe asthma: outcomes from real-world data.
    Del-Barrio-Buesa S, Narrillos-Moraza Á, García-de-Pedro J, de-Castro-Martínez FJ, Durán-García ME, Escudero-Vilaplana V, Lobato-Matilla E, Romero-Jimenez R, Chamorro-de-Vega E, Ruiz-Briones P, Garcia-Moreno FJ, Martín-Bartolomé M, Herranz A, Sanjurjo M. Del-Barrio-Buesa S, et al. Front Med (Lausanne). 2025 Aug 11;12:1635688. doi: 10.3389/fmed.2025.1635688. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40873794 Free PMC article.
  • IL1RL1 variant may affect the response to type 2 biologics in patients with severe asthma.
    Nishi K, Matsumoto H, Sunadome H, Nagasaki T, Oguma T, Tashima N, Hayashi Y, Terada S, Morita K, Yoshimura C, Nishizaka Y, Sano A, Iwanaga T, Sano H, Haraguchi R, Tohda Y, Kawaguchi T, Matsuda F, Hirai T. Nishi K, et al. ERJ Open Res. 2025 Jan 13;11(1):00448-2024. doi: 10.1183/23120541.00448-2024. eCollection 2025 Jan. ERJ Open Res. 2025. PMID: 39811553 Free PMC article.

References

    1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. (2014) 43:343–73. 10.1183/09031936.00202013 - DOI - PubMed
    1. Hekking P-PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. (2015) 135:896–902. 10.1016/j.jaci.2014.08.042 - DOI - PubMed
    1. Melero Moreno C, Quirce S, Huerta A, Uría E, Cuesta M. Economic impact of severe asthma in Spain: multicentre observational longitudinal study. J Asthma. (2019 Aug) 56(8):861–71. 10.1080/02770903.2018.1499035 - DOI - PubMed
    1. Kerkhof M, Tran TN, Soriano JB, Golam S, Gibson D, Hillyer EV, Price DB. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax 2018;73:116–24. 10.1136/thoraxjnl-2017-210531 - DOI - PMC - PubMed
    1. Zazzali JL, Broder MS, Omachi TA, Chang E, Sun GH, Raimundo K. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. (2015) 36:268–74. 10.2500/aap.2015.36.3863 - DOI - PubMed